Cervical Prostaglandin EP3 Receptors, Pregnancy
Conditions
Keywords
Cervix, EP3 receptors, Mifepristone, Prostaglandin, Receptors, Steroids
Brief summary
The purpose of this study is to determine the effect of mifepristone on the expression of three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days gestational age.
Interventions
DRUGMifepristone
Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
OTHERNon-treatment
Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
Sponsors
University of Southern California
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* good general health * ≥18 years old * seeking termination of a viable intrauterine pregnancy of ≤63 days, without any evidence of a threatened or spontaneous abortion
Exclusion criteria
* medical problems * confirmed or suspected ectopic pregnancy * having taken medications in the seven days prior to enrollment that would affect PG synthesis or metabolism of mifepristone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of expression of EP3 receptor mRNA levels in cervical tissue after the administration of mifepristone | 48 hours after the administration of mifepristone |
Secondary
| Measure | Time frame |
|---|---|
| The degree of cervical dilation after the administration of mifepristone | 48 hours after the administration of mifepristone |
Countries
United States
Outcome results
None listed